I think there are some silver linings in the comments here, from the WHO official in charge of #2019CoV#coronavirus response. Those have been hard to come by over the past couple of weeks. statnews.com/2020/02/01/top…
Dr. Ryan notes evidence from China shows fairly limited transmission in households where the virus is introduced (low “secondary attack rate”). So far there has been limited spread of infection to health care workers (this had been a major component of the SARS epidemic in 2003).
So far, most severe cases and deaths have been among adults 50 or older, and a large proportion have been people with pre-existing conditions. We’ve seen no deaths outside China so far.
We have no evidence of widespread community transmission outside China. While there has been human-to-human spread, including third generation spread at this point, outbreaks in other countries look nothing like those in the heavily affected areas in China *at this point*
How and why did is it so bad in China, then? Slow recognition and early missteps in China, an overwhelmed and politicized public health system, and authorities that placed secrecy over directly addressing an emerging health threat, it would appear.
The NY Times describes officials hiding and downplaying reports of this unusual disease early on. It wasn’t until January 20 that serious action began, after President Xi made public statements about the outbreak nytimes.com/2020/02/01/wor…
The Washington Post reports that a bureaucratic, politically-beholden and insufficiently prepared public health structure in China was quickly overwhelmed as the epidemic progressed. washingtonpost.com/world/2020/02/…
The Chinese public health and political system struggled early with this rapidly growing epidemic. When action was finally taken, it came too late to stop the large early wave of disease that was already in motion.
Since then, though, we’ve seen the Chinese mount the largest emergency public health intervention in history. The heavy-handed actions are a marked shift from the past, and likely have reduced transmission in China significantly.
We're still seeing cases/deaths from that earlier, uncontrolled stage. The next few days and weeks will tell us whether things take a turn for the better. We can hope that the emerging anecdotal evidence and silver linings mean the epidemic can indeed be curtailed.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
On a positive note, 8% of adults 65+ say they got the booster in (approx) 3 weeks since its release, and close to 40% more say they plan to get it as soon as possible.
The groups among fully vaccinated adults most likely to express they aren’t sure if the bivalent booster is recommended for them include: rural residents (54%), Hispanic adults (51%), and those without a college degree (49%).
Wonderful: a malaria vaccine is now recommended for use in high burden areas, and could save tens of thousands of lives a year who.int/news/item/06-1…
(For sense of the timing: initial Phase 3 trial results for this vaccine were published a decade ago!) nejm.org/doi/10.1056/NE…
WHO and others careful to note the vaccine is best positioned as one component of a comprehensive public health approach to malaria prevention. It is burdensome (4 shots over 18 months) and perhaps 50% effective in preventing severe malaria in kids.
Unclear how quickly it can be rolled out in African countries given the resources focused on Covid-19 vaccine distribution.
“We’re really going to have to see how the pandemic unfolds next year in terms of when countries will be ready" nytimes.com/2021/10/06/hea…
In 2022, protein-based COVID-19 vaccines could be what mRNA vaccines have not been for many lower-income countries: accessible and relatively easy to manage. Slower out of the gate than other vaccines, there are now several candidates on the near horizon. 1/
They are refrigerator stable, have promising safety profiles, and efficacy that in many cases rivals mRNA vaccines. Protein vaccines are also readily scalable, with good prospects for technology transfer 2/ nature.com/articles/d4158…
Novavax, delayed for months with manufacturing and supply woes, recently filed for authorization in several countries and WHO for its protein-based vaccine. COVAX has already purchased more Novavax doses (900 M) than any other vaccine in its portfolio 3/ launchandscalefaster.org/covid-19/vacci…
Over 7 billion Covid-19 vaccine doses have been produced globally to date, with >1.35 billion more doses produced each month now.
Sinovac and Sinopharm produce the greatest number of vaccines monthly, with Pfizer and AstraZeneca not far behind. 1/
By the end of this year the world is likely to produce over 12 billion vaccine doses of all vaccine types.
By June 2022 the number produced could reach double that – 24 billion doses (assuming all goes well, and it usually doesn’t) 2/
Even after reserving doses for boosters, Western countries are likely to accumulate large stockpiles of vaccines over the coming months, perhaps as many as 1.2 billion doses by the end of this year.
These “surplus” doses could be redistributed to lower income countries. 3/
Keeping a wary eye on Covid trends in South America. The good: cases/deaths there have come down from devastating peaks a few months back, and there’s progress on vaccinations. The bad: Delta may have only begun to circulate, and questions about vaccine efficacy
Most countries in the region have fully vaccinated between 20 and 40% of their populations; Chile and Uruguay stand out, with >70% fully vaccinated. Countries use a mix of vaccines, mostly Chinese inactivated vaccines (Sinovac and Sinopharm), plus some Pfizer & AstraZeneca
Chinese vaccines have lower effectiveness vs symptomatic disease but protect vs hospitalizations and death.
Chile estimated the Sinovac VE vs. symptomatic Covid at 58%, and 86% vs hospitalization. For Pfizer: 88% and 97%, AZ: 68% and 100%, respectively minsal.cl/wp-content/upl…
Some initial thoughts on full FDA approval of the Pfizer vaccine and what it might mean for vaccine acceptance in the US, based on @KFF polling and policy work
A commonly referenced finding from KFF's vaccine monitor is that 3 in 10 unvaccinated people reported they'd be more likely to get the vaccine upon full FDA approval kff.org/coronavirus-co…
Still, I don't think it means that if unvaccinated people hear the news about full FDA approval 3 in 10 of will all of a sudden decide to get the shot based on that alone.